메뉴 건너뛰기




Volumn 38, Issue 7, 2006, Pages 477-482

Comparable kinetics of myeloablation between fludarabine/full-dose busulfan and fludarabine/melphalan conditioning regimens in allogeneic peripheral blood stem cell transplantation

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; BUSULFAN; COTRIMOXAZOLE; DAPSONE; FLUCONAZOLE; FLUDARABINE; FOSCARNET; GANCICLOVIR; MELPHALAN; METHOTREXATE; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PENTAMIDINE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TACROLIMUS; THYMOCYTE ANTIBODY;

EID: 33749028469     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/sj.bmt.1705480     Document Type: Article
Times cited : (19)

References (27)
  • 1
    • 0027280192 scopus 로고
    • Fludarabine: An active agent in the treatment of previously-treated and untreated low-grade non-Hodgkin's lymphoma
    • Zinzani PL, Lauria F, Rondelli D, Benfenati D, Raspadori D, Bocchia M et al. Fludarabine: An active agent in the treatment of previously-treated and untreated low-grade non-Hodgkin's lymphoma. Ann Oncol 1993; 4: 575-578.
    • (1993) Ann Oncol , vol.4 , pp. 575-578
    • Zinzani, P.L.1    Lauria, F.2    Rondelli, D.3    Benfenati, D.4    Raspadori, D.5    Bocchia, M.6
  • 2
    • 4143059279 scopus 로고    scopus 로고
    • The role of fludarabine in the treatment of follicular and mantle cell lymphoma
    • Lenz G, Hiddemann W, Dreyling M. The role of fludarabine in the treatment of follicular and mantle cell lymphoma. Cancer 2004; 101: 883-893.
    • (2004) Cancer , vol.101 , pp. 883-893
    • Lenz, G.1    Hiddemann, W.2    Dreyling, M.3
  • 3
    • 20044368632 scopus 로고    scopus 로고
    • Rituximab in combination with fludarabine chemotherapy in low-grade or follicular lymphoma
    • Czuczman MS, Koryzna A, Mohr A, Stewart C, Donohue K, Blumenson L et al. Rituximab in combination with fludarabine chemotherapy in low-grade or follicular lymphoma. J Clin Oncol 2005; 23: 694-704.
    • (2005) J Clin Oncol , vol.23 , pp. 694-704
    • Czuczman, M.S.1    Koryzna, A.2    Mohr, A.3    Stewart, C.4    Donohue, K.5    Blumenson, L.6
  • 4
    • 0034893776 scopus 로고    scopus 로고
    • Fludarabine plus cyclophosphamide is an efficient treatment for advanced chronic lymphocytic leukaemia (CLL): Results of a phase II study of the German CLL Study Group
    • Hallek M, Schmitt B, Wilhelm M, Busch R, Krober A, Fostitsch HP et al. Fludarabine plus cyclophosphamide is an efficient treatment for advanced chronic lymphocytic leukaemia (CLL): Results of a phase II study of the German CLL Study Group. Br J Haematol 2001; 114: 342-348.
    • (2001) Br J Haematol , vol.114 , pp. 342-348
    • Hallek, M.1    Schmitt, B.2    Wilhelm, M.3    Busch, R.4    Krober, A.5    Fostitsch, H.P.6
  • 5
    • 0029830510 scopus 로고    scopus 로고
    • Efficacy of fludarabine as an immunosuppressor for bone marrow transplantation conditioning: Preliminary results
    • Terenzi A, Aristei C, Aversa F, Perruccio K, Chionne F, Raymondi C et al. Efficacy of fludarabine as an immunosuppressor for bone marrow transplantation conditioning: Preliminary results. Transplant Proc 1996; 28: 3101.
    • (1996) Transplant Proc , vol.28 , pp. 3101
    • Terenzi, A.1    Aristei, C.2    Aversa, F.3    Perruccio, K.4    Chionne, F.5    Raymondi, C.6
  • 6
    • 20844457922 scopus 로고    scopus 로고
    • Allogeneic hematopoietic stem cell transplantation with reduced intensity conditioning in intermediate or high risk patients with myelofibrosis with myeloid metaplasia
    • Rondelli D, Barosi G, Bacigalupo A, Prchal JT, Popat U, Alessandrino EP et al. Allogeneic hematopoietic stem cell transplantation with reduced intensity conditioning in intermediate or high risk patients with myelofibrosis with myeloid metaplasia. Blood 2005; 105: 4115-4119.
    • (2005) Blood , vol.105 , pp. 4115-4119
    • Rondelli, D.1    Barosi, G.2    Bacigalupo, A.3    Prchal, J.T.4    Popat, U.5    Alessandrino, E.P.6
  • 7
    • 0035254219 scopus 로고    scopus 로고
    • Melphalan and purine analog-containing preparative regimens: Reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation
    • Giralt S, Thall PF, Khouri I, Wang X, Braunschweig I, Ippolitti C et al. Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation. Blood 2001; 97: 631-637.
    • (2001) Blood , vol.97 , pp. 631-637
    • Giralt, S.1    Thall, P.F.2    Khouri, I.3    Wang, X.4    Braunschweig, I.5    Ippolitti, C.6
  • 8
    • 2942677243 scopus 로고    scopus 로고
    • Graft-versus-lymphoma effect in relapsed peripheral T-cell non-Hodgkin's lymphomas after reduced-intensity conditioning followed by allogeneic transplantation of hematopoietic cells
    • Corradini P, Dodero A, Zallio F, Caracciolo D, Casini M, Bregni M et al. Graft-versus-lymphoma effect in relapsed peripheral T-cell non-Hodgkin's lymphomas after reduced-intensity conditioning followed by allogeneic transplantation of hematopoietic cells. J Clin Oncol 2004; 22: 2172-2176.
    • (2004) J Clin Oncol , vol.22 , pp. 2172-2176
    • Corradini, P.1    Dodero, A.2    Zallio, F.3    Caracciolo, D.4    Casini, M.5    Bregni, M.6
  • 9
    • 0034789233 scopus 로고    scopus 로고
    • Thiotepa and fludarabine (TT-FLUDA) as conditioning regimen in poor candidates for conventional allogeneic hemopoietic stem cell transplant
    • Alessandrino EP, Bernasconi P, Colombo AA, Caldera D, Bonfichi M, Pagnucco G et al. Thiotepa and fludarabine (TT-FLUDA) as conditioning regimen in poor candidates for conventional allogeneic hemopoietic stem cell transplant. Ann Hematol 2001; 80: 521-524.
    • (2001) Ann Hematol , vol.80 , pp. 521-524
    • Alessandrino, E.P.1    Bernasconi, P.2    Colombo, A.A.3    Caldera, D.4    Bonfichi, M.5    Pagnucco, G.6
  • 10
    • 0032006125 scopus 로고    scopus 로고
    • Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases
    • Slavin S, Nagler A, Naparstek E, Kapelushnik Y, Aker M, Cividalli G et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 1998; 91: 756-763.
    • (1998) Blood , vol.91 , pp. 756-763
    • Slavin, S.1    Nagler, A.2    Naparstek, E.3    Kapelushnik, Y.4    Aker, M.5    Cividalli, G.6
  • 11
    • 20044391419 scopus 로고    scopus 로고
    • Pilot study of reduced-intensity conditioning followed by allogeneic stem cell transplantation from related and unrelated donors in patients with myelofibrosis
    • Kroger N, Zabelina T, Schieder H, Panse J, Ayuk F, Stute N et al. Pilot study of reduced-intensity conditioning followed by allogeneic stem cell transplantation from related and unrelated donors in patients with myelofibrosis. Br J Haematol 2005; 128: 690-697.
    • (2005) Br J Haematol , vol.128 , pp. 690-697
    • Kroger, N.1    Zabelina, T.2    Schieder, H.3    Panse, J.4    Ayuk, F.5    Stute, N.6
  • 12
    • 9444239769 scopus 로고    scopus 로고
    • Allogeneic hematopoietic cell transplantation after fludarabine and 2 Gy total body irradiation for relapsed and refractory mantle cell lymphoma
    • Maris MB, Sandmaier BM, Storer BE, Chauncey T, Stuart MJ, Maziarz RT et al. Allogeneic hematopoietic cell transplantation after fludarabine and 2 Gy total body irradiation for relapsed and refractory mantle cell lymphoma. Blood 2004; 104: 3535-3542.
    • (2004) Blood , vol.104 , pp. 3535-3542
    • Maris, M.B.1    Sandmaier, B.M.2    Storer, B.E.3    Chauncey, T.4    Stuart, M.J.5    Maziarz, R.T.6
  • 13
    • 0032558759 scopus 로고    scopus 로고
    • Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype
    • Aversa F, Tabilio A, Velardi A, Cunningham I, Terenzi A, Falzetti F et al. Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype. N Engl J Med 1998; 339: 1186-1193.
    • (1998) N Engl J Med , vol.339 , pp. 1186-1193
    • Aversa, F.1    Tabilio, A.2    Velardi, A.3    Cunningham, I.4    Terenzi, A.5    Falzetti, F.6
  • 14
    • 3242810563 scopus 로고    scopus 로고
    • Once-daily intravenous busulfan and fludarabine: Clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS
    • de Lima M, Couriel D, Thall PF, Wang X, Madden T, Jones R et al. Once-daily intravenous busulfan and fludarabine: Clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS. Blood 2004; 104: 857-864.
    • (2004) Blood , vol.104 , pp. 857-864
    • de Lima, M.1    Couriel, D.2    Thall, P.F.3    Wang, X.4    Madden, T.5    Jones, R.6
  • 15
    • 0036401558 scopus 로고    scopus 로고
    • Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: Study of pharmacokinetics and early clinical outcomes
    • Russell JA, Tran HT, Quinlan D, Chaudhry A, Duggan P, Brown C et al. Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: Study of pharmacokinetics and early clinical outcomes. Biol Blood Marrow Transplant 2002; 8: 468-476.
    • (2002) Biol Blood Marrow Transplant , vol.8 , pp. 468-476
    • Russell, J.A.1    Tran, H.T.2    Quinlan, D.3    Chaudhry, A.4    Duggan, P.5    Brown, C.6
  • 16
    • 2042454565 scopus 로고    scopus 로고
    • Conditioning with fludarabine and targeted busulfan for transplantation of allogeneic hematopoietic stem cells
    • Bornhauser M, Storer B, Slattery JT, Appelbaum FR, Deeg HJ, Hansen J et al. Conditioning with fludarabine and targeted busulfan for transplantation of allogeneic hematopoietic stem cells. Blood 2003; 102: 820-826.
    • (2003) Blood , vol.102 , pp. 820-826
    • Bornhauser, M.1    Storer, B.2    Slattery, J.T.3    Appelbaum, F.R.4    Deeg, H.J.5    Hansen, J.6
  • 17
    • 0034567061 scopus 로고    scopus 로고
    • Acute safety and pharmacokinetics of intravenous busulfan when used with oral busulfan and cyclophosphamide as pretransplantation conditioning therapy: A phase I study
    • Andersson BS, Madden T, Tran HT, Hu WW, Blume KG, Chow DS et al. Acute safety and pharmacokinetics of intravenous busulfan when used with oral busulfan and cyclophosphamide as pretransplantation conditioning therapy: A phase I study. Biol Blood Marrow Transplant 2000; 6: 548-554.
    • (2000) Biol Blood Marrow Transplant , vol.6 , pp. 548-554
    • Andersson, B.S.1    Madden, T.2    Tran, H.T.3    Hu, W.W.4    Blume, K.G.5    Chow, D.S.6
  • 18
    • 0024345093 scopus 로고
    • Pharmacokinetics of busulfan: Correlation with veno-occlusive disease in patients undergoing bone marrow transplantation
    • Grochow LB, Jones RJ, Brundrett RB, Braine HG, Chen TL, Saral R et al. Pharmacokinetics of busulfan: Correlation with veno-occlusive disease in patients undergoing bone marrow transplantation. Cancer Chemother Pharmacol 1989; 25: 55-61.
    • (1989) Cancer Chemother Pharmacol , vol.25 , pp. 55-61
    • Grochow, L.B.1    Jones, R.J.2    Brundrett, R.B.3    Braine, H.G.4    Chen, T.L.5    Saral, R.6
  • 20
    • 0034791846 scopus 로고    scopus 로고
    • Intravenous busulphan for conditioning before autologous or allogeneic human blood stem cell transplantation
    • Schuler US, Renner UD, Kroschinsky F, Johne C, Jenke A, Naumann R et al. Intravenous busulphan for conditioning before autologous or allogeneic human blood stem cell transplantation. Br J Haematol 2001; 114: 944-950.
    • (2001) Br J Haematol , vol.114 , pp. 944-950
    • Schuler, U.S.1    Renner, U.D.2    Kroschinsky, F.3    Johne, C.4    Jenke, A.5    Naumann, R.6
  • 21
    • 0037085757 scopus 로고    scopus 로고
    • Allogeneic blood cell transplantation following reduced-intensity conditioning is effective therapy for olde patients with myelofibrosis with myeloid metaplasia
    • Devine SM, Hoffman R, Verma A, Shah R, Bradlow BA, Stock W et al. Allogeneic blood cell transplantation following reduced-intensity conditioning is effective therapy for olde patients with myelofibrosis with myeloid metaplasia. Blood 2002; 99: 2255-2258.
    • (2002) Blood , vol.99 , pp. 2255-2258
    • Devine, S.M.1    Hoffman, R.2    Verma, A.3    Shah, R.4    Bradlow, B.A.5    Stock, W.6
  • 22
    • 0033008061 scopus 로고    scopus 로고
    • Rapid quantification of mixed chimerism using multiplex amplification of short tandem repeat markers and fluorescence detection
    • Thiede C, Florek M, Bornhauser M, Ritter M, Mohr B, Brendel C et al. Rapid quantification of mixed chimerism using multiplex amplification of short tandem repeat markers and fluorescence detection. Bone Marrow Transplant 1999; 23: 1055-1060.
    • (1999) Bone Marrow Transplant , vol.23 , pp. 1055-1060
    • Thiede, C.1    Florek, M.2    Bornhauser, M.3    Ritter, M.4    Mohr, B.5    Brendel, C.6
  • 25
    • 0025860239 scopus 로고
    • Chronic graft-versus-host disease and other late complications of bone marrow transplantation
    • Sullivan KM, Agura E, Anasetti C, Appelbaum F, Badger C, Bearman S et al. Chronic graft-versus-host disease and other late complications of bone marrow transplantation. Semin Hematol 1991; 28: 250-259.
    • (1991) Semin Hematol , vol.28 , pp. 250-259
    • Sullivan, K.M.1    Agura, E.2    Anasetti, C.3    Appelbaum, F.4    Badger, C.5    Bearman, S.6
  • 26
    • 0037562931 scopus 로고    scopus 로고
    • Intravenous busulfan-based conditioning prior to allogeneic hematopoietic stem cell transplantation: Myeloablation with reduced toxicity
    • Shimoni A, Bielorai B, Toren A, Hardan I, Avigdor A, Yeshurun M et al. Intravenous busulfan-based conditioning prior to allogeneic hematopoietic stem cell transplantation: Myeloablation with reduced toxicity. Exp Hematol 2003; 31: 428-434.
    • (2003) Exp Hematol , vol.31 , pp. 428-434
    • Shimoni, A.1    Bielorai, B.2    Toren, A.3    Hardan, I.4    Avigdor, A.5    Yeshurun, M.6
  • 27
    • 4444242994 scopus 로고    scopus 로고
    • Dose modification protocol using intravenous busulfan (Busulfex) and cyclophosphamide followed by autologous or allogeneic peripheral blood stem cell transplantation in patients with hematologic malignancies
    • Williams CB, Day SD, Reed MD, Copelan EA, Bechtel T, Leather HL et al. Dose modification protocol using intravenous busulfan (Busulfex) and cyclophosphamide followed by autologous or allogeneic peripheral blood stem cell transplantation in patients with hematologic malignancies. Biol Blood Marrow Transplant 2004; 10: 614-623.
    • (2004) Biol Blood Marrow Transplant , vol.10 , pp. 614-623
    • Williams, C.B.1    Day, S.D.2    Reed, M.D.3    Copelan, E.A.4    Bechtel, T.5    Leather, H.L.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.